This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bad Medicine Hits the IPO Market

The initial public offering market for health care ended the year in much the same way it behaved throughout 2004 -- lots of deals and lots of disappointments.

The good news is that underwriters engineered 50 public offerings of medical companies in 2004, which is more than the combined total of 44 from the prior three years.

The not-so-good news is that of those 50 IPOs, underwriters cut offering prices on a whopping 60% of the issues to bring them to market, according to Greenwich, Conn.-based Renaissance Capital. For all other IPOs, the rate of discounted offerings was 29.5%.

"The only IPO market faux pas was the medical market," said David Menlow, president of IPO Financial Network in Millburn, N.J. "It was a very trying time for us to see this force-feeding of issues" by underwriters. "Investors didn't want these deals at those prices."

Many discounted deals involved biotech companies; some IPOs were discounted more than once before finding willing investors. Many of those health care IPO offering prices were more than 40% below the initial range.

Renaissance Capital calculates the discount by dividing the offering price by the midpoint in the original price range. Thus, Memory Pharmaceuticals (MEMY), which had a $7 offering price, went public at 50% below the midpoint of its original price range of $13 to $15.

Memory was one of 30 medical IPOs that hit the market below their original price ranges. In fact, 14 of the 15 IPOs with the biggest rates of discounted offering prices were health care companies.

For medical companies, "2004 was a good year in general because they were able to raise money," said Melanie Hase, a Renaissance Capital analyst. "But the negative was that companies in early-stage testing [of products] were priced at a discount. It was great that investors were willing to invest, but they weren't willing to take such a risk at an early stage."

Healthy Returns
The best-performing health care IPOs in 2004
Company & Ticker Dec. 29 Closing Price Change From Offering Price
Kinetic Concepts (KCI) $75.93 +153.1%
Syneron Medical (ELOS) 30.18 151.5
Eyetech Pharmaceuticals (EYET) 45.27 115.6
Source: Renaissance Capital

Stock Market Ills
The worst-performing health care IPOs in 2004
Company & Ticker Dec. 29 Closing Price Change From Offering Price
Xcyte Therapies (XCYT) $2.66 -66.8%
Corgentech (CGTK) 8.11 -49.3
Corcept Therapeutics (CORT) 6.75 -43.8
Source: Renaissance Capital

Seventeen health care IPOs, or 34% of the total, went public at prices above their original price range. Among other IPOs, the rate of offering prices exceeding their price ranges was 13.9%.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CORT $3.39 0.00%
ELOS $7.15 0.00%
PFE $29.03 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs